Business
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
- Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study - Because of its
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\n- Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study\n\n- Because of its potency, bamlanivimab provides a therapeutic foundation to be administered with another antibody to expand the protection against viral variants\n\n- Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway\n\n- Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world’s first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2\n\n- Since EUA, bamlanivimab has been used to treat approximately 400,000 high-risk COVID-19 patients in the U.S. alone and has been authorized in more than 15 countries\n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-binding domain (RBD) and inhibiting critical interactions with the angiotensin converting enzyme 2 (ACE2) cellular receptor necessary for viral entry. Data generated in a preclinical model showed prophylactic treatment with bamlanivimab resulted in significant decreases in viral load and replication in the upper and lower respiratory tracts after SARS-CoV-2 exposure, indicating the potential of bamlanivimab to reduce viral shedding and transmission. These data, which were generated prior to initiating clinical trials in June 2020 and published today, support the observed substantial clinical efficacy of bamlanivimab in treating and preventing COVID-19.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005386/en/The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This...